drugset / Trial / NCT04985604
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a Phase 2, multi-center, open-label to evaluate the efficacy and safety of tovorafenib (DAY101) in participants ≥12 years of age with recurrent or progressive melanoma or solid tumors with BRAF fusion or CRAF/RAF1 fusions or amplification.
Timeline
- Start
- 2021-07-15
- Primary completion
- 2024-07-08
- Completion
- 2024-07-08
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tovorafenib | Small molecule | — | Oral |